Real Money: Ketamine beating psilocybin in race for patients

This is an interesting article that includes some of my work studying ketamine-assisted psychotherapy. Compared to other psychedelics, like MDMA and psilocybin, ketamine has a leg up on the race for FDA approval. It has a growing number of psychiatric off-label uses, and it’s derivative, esketamine or Spravato, recently received FDA approval for treatment-resistant depression. Take a look if you’re interested.